Scientific Literature

Learn more about external studies conducted on some of our key technologies and assays, including platelet function analysis, P2Y12 testing*, D-dimer testing, LOCI technology, and preanalytical variables in coagulation testing.


Sysmex CS-5100 System*

Evaluation of the automated coagulation analyzer CS-5100 and its utility in high throughput laboratories

Clin Chem Lab Med. 2014 Apr; Advance online publication. doi: 10.1515/cclm-2013-1094



Platelet Function Analysis (Dade PFA Collagen/EPI Test Cartridge)

A practical concept for preoperative identification of patients with impaired primary hemostasis.
Clin Appl Thromb Hemost. 2004 Jul;10(3):195-204.

 

A practical concept for preoperative management of patients with impaired primary hemostasis.
Clin Appl Thromb Hemost. 2004 Apr;10(2):155-66.



Platelet Function Analysis (Dade PFA Collagen/ADP Test Cartridge)

Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases.
Blood. 1998 Feb;91(4):1325-1331.

 

Clinical utility of the PFA-100.
Semin Thromb Hemost. 2008 Nov;34(8):709-33.

 

Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS.
J Thromb Haemost. 2006 Sep;4:1-6.

 

Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
Circulation. 2009 Dec 22;120(25):2586-97.



INNOVANCE PFA P2Y Assay*

The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition.
Platelets. 2011;22(1):19-25.

 

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.

JAMA. 2011 Jun 1;305(21):2174.



von Willebrand (BC von Willebrand Reagent and INNOVANCE VWF Ac Assay)*

Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
J Thromb Haemost. 2007;5:1115–1124.

 

Novel gain-of-function mutations of platelet glycoprotein Iba by valine mutagenesis in the Cys209-Cys248 disulfide loop.
J Biol Chem. 2000;275:27663-70.

 

The diagnosis, evaluation, and management of von Willebrand disease. NHLBI VWD Expert Panel.
NIH Publication No. 08-5833, 2008.

 

Laboratory diagnosis of von Willebrand disease.
Hämostaseologie. 2010;30:203–206.



INNOVANCE D-Dimer Assay

A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism.
Thromb Haemost. 2008;100:505–512.

 

Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer.
Clin Chem. 2008;54:2042-2048.

 

Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study.
Haematologica. 2008 June;93(6):900-907.

 

The diagnostic management of acute venous thromboembolism during pregnancy: recent advancements and unresolved issues.
Thrombosis Research. 2011;127(Suppl. 3):S13-S16.

 

An age-adapted approach for the use of D-dimers in the exclusion of deep venous thrombosis.
Am J Hematol. 2009;84:488-491.

 

D-Dimer for venous thromboembolism diagnosis: 20 years later.
J Thromb Haemost. 2008;6(7):1059-71.
 

D-dimer assays in diagnosis and management of thrombotic and bleeding disorders.
Semin Thromb Hemost. 2012;38(7):673-82.

 

The diagnosis and treatment of venous thromboembolism.
Hematology Am Soc Hematol Educ Program. 2013;2013:457-63.

 

D-dimer testing in laboratory practice.
Clin Chem. 2011;57(9):1256-62.

 

Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study.
JAMA. 2014;311(11):1117-24.

 

The combination of four different clinical decision rules and an age-adjusted D-dimer cut-off increases the number of patients in whom acute pulmonary embolism can safely be excluded.
Thromb Haemost. 2012;107(1):167-71.

 

D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study.
Blood. 2014;124(2):196-203.

 

Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
Thromb Haemost. 2014;112(5).

 

Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses.
PLoS One. 2013;8(2):e55175.

 

Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence.
Ann Med. 2014:1-8.

 

Meta-analysis of usefulness of d-dimer to diagnose acute aortic dissection.
Am J Cardiol. 2011;107(8):1227-34.

 

D-Dimer levels at different stages of pregnancy in Australian women: a single center study using two different immunoturbidimetric assays.
Thromb Res. 2012;130(3):e171-7.

 

D-dimer in preeclampsia: systematic review and meta-analysis.
Clin Chim Acta. 2012;414:166-70.

 

The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview.
J Thromb Haemost. 2007;5(3):604-6.

 

Evaluation of the Innovance d-dimer assay for the diagnosis of disseminated intravascular coagulopathy in different clinical settings.
Clin Appl Thromb Hemost. 2014;20(1):91-7.



ProC Global Assay*

ProC® Global: a functional screening test that predicts recurrent venous thromboembolism.
Thromb Haemost. 2005;93:600-4.

 

Laboratory methods in the haemostatic laboratory.
Thromb Haemost. 2006;96:545-6.

 

Evaluation of ProC® Global assay in women with a history of venous thromboembolism on hormonal therapy.
Thromb Haemost. 2006;96:578-83.

 

Modification of the ProC® Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
Blood Coagul Fibrinolysis. 2001;12:569-576.



INNOVANCE Antithrombin Assay

Clinical multicenter evaluation of a new FXa-based Antithrombin assay.
Int J Lab Hematol. 2011 Oct;33(5):498-506.



LOCI Technology

Immunoassays for diagnosis of coagulation disorders.
Hämostaseologie. 2010 Apr.

 

Coagulation assays based on the Luminescent Oxygen Channeling Immunoassay technology.
Clin Chem Lab Med. 2011;49(5):855-860.

 

Luminescent oxygen channeling assay (LOCITM): sensitive, broadly applicable homogenous immunoassay method.

Clin Chem. 1996;42(9):1518-1526.



Preanalytical Sample Integrity

Errors in laboratory medicine.
Clin Chem. 2002;48(5):691-698.

 

Preanalytic error tracking in a laboratory medicine department: results of a 1-year experience.
Clin Chem. 2006;52(7):1442-3.

 

Preanalytical and postanalytical variables: the leading causes of diagnostic errors in hemostasis?
Sem Thromb Hemost. 2008;34(37):612-634.

 

Mistakes in a stat laboratory: types and frequency.
Clin Chem. 1997;43(8):1348-1351.

 

Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays.
CLSI Guidelines. Approved Guideline-Fifth Edition; H21-A5.



Share this page:

*Not available for sale in the U.S. Product availability varies by country.

The Siemens Web Site may contain hyperlinks to the Web pages of third parties. Siemens accepts no liability for the contents of such Web pages and does not make representations about or endorse such Web pages or their contents as its own, as Siemens does not control the information on such Web pages and is not responsible for the contents and information given thereon. The use of such Web pages shall be at the sole risk of the User.

The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.